Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deoxypodophyllotoxin is a natural flavonolignan and a derivative of podophyllotoxin. It is classified as a small molecule tubulin inhibitor with potent antimitotic activity. Deoxypodophyllotoxin destabilizes microtubules by inhibiting tubulin polymerization and exhibits significant antitumor effects through cell cycle arrest and induction of apoptosis. It also inhibits angiogenesis and has demonstrated anti-inflammatory and antiviral properties. Mechanistically, it can inhibit the HIF-1α signaling pathway (reducing glycolysis in cancer cells), competitively bind to EGFR and MET kinases (suppressing their downstream signaling), induce reactive oxygen species (ROS) generation leading to endoplasmic reticulum stress and apoptosis via multi-caspase activation[3][4][6]. The compound is being developed primarily for oncology indications such as advanced malignant solid neoplasms[1]. Its originator organization is Shenyang Pharmaceutical University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deoxypodophyllotoxin.